<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574453</url>
  </required_header>
  <id_info>
    <org_study_id>OPIRA/0519/MD</org_study_id>
    <nct_id>NCT04574453</nct_id>
  </id_info>
  <brief_title>Study To Assess The Efficacy And Safety Of The Medical Device Iracross Versus Iraline Administered Intra-Articular To Patients With Knee Osteoarthritis</brief_title>
  <official_title>A Randomized, Open Label, Paralel Goup Study To Assess With A Non- Inferiority Hypothesis The Efficacy And Safety Of The Medical Device Iracross (Crosslinked 2% Hyaluronic Acid) Versus The Medical Device Iraline (Linear 2% Hyaluronic Acid), Administered Intra-Articular To Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.R.A. Istituto Ricerche Applicate S.p.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Opera Contract Research Organization a Tigermed company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>I.R.A. Istituto Ricerche Applicate S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison with a non-inferiority design at 12 and 24 weeks on a larger scale is real to&#xD;
      objectively evaluate the composite measurement of ROM, pain and basic activities like walking&#xD;
      or performing daily activities (QoL) in a population with a large coverage of age and levels&#xD;
      of physical activity (from no physical activity history to athletes).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After giving their consent, subjects will undergo a screening visit to determine eligibility&#xD;
      for study entry. After randomization, subjects will have administered medical device Iracross&#xD;
      or Iraline. For subjects allocated to Iracross, medical device will be administered only at&#xD;
      first visit and for subjects allocated to Iraline, medical device will be administered at&#xD;
      visit 1, visit,2, visit 3 and optional for visit 4 and visit 5.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Actual">February 10, 2021</completion_date>
  <primary_completion_date type="Actual">February 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled, open label, multicentre study with two parallel groups of patients and a non-inferiority hypothesis.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Range Of Motion and Visual Analogue Scale</measure>
    <time_frame>180 days</time_frame>
    <description>Change in ROM and VAS for pain (at rest), at 180 (± 4 days) days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician Efficacy Global Evaluation</measure>
    <time_frame>180 days</time_frame>
    <description>Score of Physician Efficacy Global Evaluation at final visit. Minimum value is4-poor efficacy and maximum value is 1- very good efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale Evaluation</measure>
    <time_frame>180 days</time_frame>
    <description>VAS for pain (on moving and on pressing). Minimum score is 0 and it means no pain. Maximum score is 100 and represents the maximum pain that patient can suffer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score</measure>
    <time_frame>180 days</time_frame>
    <description>Changes in KOOS score from first visit to final visit. The min value is 0 and the max value 100, were the min value represents no problem and max value represents extreme problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NSAID consumption</measure>
    <time_frame>180 days</time_frame>
    <description>Incidence of NSAID consumption from first visit to final visit</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AE, SAE, ADE, SADE, DD incidence.</measure>
    <time_frame>180 days</time_frame>
    <description>To investigate the overall safety and tolerability of the two medical devices during the by overall study period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Physician Global Tolerability</measure>
    <time_frame>180 days</time_frame>
    <description>Percentage of patients with &quot;excellent&quot; evaluations in the Physician Global Tolerability Evaluation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Iracross</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 course of IRACROSS (crosslinked 2% Hyaluronic Acid) at baseline, consisting of a mono-dose intra-articular administration (2ml).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iraline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 course of IRALINE (linear 2% Hyaluronic Acid); each course consists of 3-5 intra-articular administrations (2ml) at weekly intervals (from week 1 to 3, 4 or 5, depending on each patient's need)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Iracross</intervention_name>
    <description>Administration of max 2ml of Iracross at first visit</description>
    <arm_group_label>Iracross</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Iraline</intervention_name>
    <description>Administration of maximum 2 ml of Iraline at visit 1 to visit 3, 4 and 5 depending of suject's need</description>
    <arm_group_label>Iraline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged between 40 and 80 years&#xD;
&#xD;
          2. Symptomatic knee osteoarthritis as defined by the American College of Rheumatology&#xD;
             (ACR) criteria; (for subjects with OA at both knees, the most painful one will be&#xD;
             included in the study only, respecting KL grade II or III);&#xD;
&#xD;
          3. Ambulant without assistance;&#xD;
&#xD;
          4. Kellgren-Lawrence grade II or III on X-ray performed at maximum 6 months before&#xD;
             screening;&#xD;
&#xD;
          5. VAS knee pain ≥40 at screening and 30 days before;&#xD;
&#xD;
          6. At least 30 days before screening oral/parenteral corticosteroid or NSAIDs (10 mg&#xD;
             prednisone) administration.&#xD;
&#xD;
          7. Signed Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unstable knee;&#xD;
&#xD;
          2. Varus or valgus ≥ 15 degrees;&#xD;
&#xD;
          3. Active malignancy;&#xD;
&#xD;
          4. Knee trauma or lose body parts 1 year before screening;&#xD;
&#xD;
          5. Rheumatoid Arthritis, avascular necrosis, fibromyalgia;&#xD;
&#xD;
          6. Use of potent analgesics 15 days (different from ≤ 10 mg prednisone);&#xD;
&#xD;
          7. Intra-articular HA or corticosteroid injection within 6 months before screening;&#xD;
&#xD;
          8. Arthroscopic or knee open surgery within 12 months before screening;&#xD;
&#xD;
          9. Body Mass Index (BMI) ≥ 40 kg/m2;&#xD;
&#xD;
         10. Active infection around the injection site;&#xD;
&#xD;
         11. Use of anticoagulants or history of thrombocytopenia;&#xD;
&#xD;
         12. Concomitant use of disease-modifying antirheumatic drugs (DMARDs), anaesthetics;&#xD;
&#xD;
         13. Known sensitivity to HA or DVS;&#xD;
&#xD;
         14. Pregnancy, breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Puenea</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fizio Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fizio Center</name>
      <address>
        <city>Timişoara</city>
        <state>Timis</state>
        <zip>300211</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

